Indian stocks: Visit www.stage2stocks.com →

Unicycive Therapeutics, Inc.

Stage 4 · Declining · week 12

As of Oct 22, 2026, Unicycive Therapeutics is in Stage 4, the downtrend phase, now in week 12 (since Aug 3, 2026). It closed at $3.94, 54.0% below its 52-week high and below its 200-day average, which is falling.

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. More about the company

$3.94
+0.25% today
$108M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is UNCY early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 19w
S4 17w
S2 29w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 2w → S4 19w → S1 6w → S2 10w → S3 7w → S4 17w → S1 12w → S2 6w → S3 9w → S2 11w → S3 1w → S4 13w → S1 8w → S2 29w → S3 3w → S4 12w current
Total tracked: 165 weeks across 16 stage runs.

UNCY among Biotechnology251st of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…251UNCYStage 4 · wk 1239−18.1%
vs 52W High
-54.0%
$3.36 lo$8.56 hi
54.0% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 12
1w13w26w
Week 12, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-36.2%
200 DMA: $6.17 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.82x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-18.1%
3M
-27.0%
6M
-46.4%
YTD
-32.1%
1Y
-20.2%
Scan Membership
Breakout Watch
Latest: 2025-05-02
4 appearances in last 60 days. First seen: 2023-03-15.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 12 · Vol 0.82x
2026-10-21S4
Wk 12 · Vol 1.54x
2026-10-20S4
Wk 12 · Vol 1.38x
2026-10-19S4
Wk 11 · Vol 1.30x
2026-10-16S4
Wk 11 · Vol 1.29x
2026-10-15S4
Wk 11 · Vol 1.05x
2026-10-14S4
Wk 11 · Vol 1.43x
2026-10-13S4
Wk 11 · Vol 2.24x
2026-10-12S4
Wk 10 · Vol 1.12x
2026-10-09S4
Wk 10 · Vol 0.67x
2026-10-08S4
Wk 10 · Vol 1.42x
2026-10-07S4
Wk 10 · Vol 0.71x
Moving averages & range
50 DMA
$4.75
200 DMA
$6.17
52W High
$8.56
52W Low
$3.36
5D Low
$3.36
Resistance levels (recent highs)
20d High
$4.70
60d High
$5.63
120d High
$8.56
250d High
$8.56
Next resistance
+19.2%
to 20d High
ROE
-101.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 2.1

Unicycive Therapeutics: quick answers

What stage is Unicycive Therapeutics in?

As of Oct 22, 2026, Unicycive Therapeutics (UNCY) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 3, 2026 and is in week 12. What the four stages mean

Is Unicycive Therapeutics in an uptrend?

No. Unicycive Therapeutics is in a Stage 4 downtrend. It trades 36.2% below its 200-day average, which is falling.

How far is Unicycive Therapeutics from its 52-week high?

Unicycive Therapeutics closed at $3.94 on Oct 22, 2026, 54.0% below its 52-week high of $8.56. Its 52-week low is $3.36.

How has Unicycive Therapeutics performed over the past year?

As of Oct 22, 2026, Unicycive Therapeutics is down 20.2% over the past year and down 32.1% so far in 2026.

Which sector and industry is Unicycive Therapeutics in?

Unicycive Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.